Eli Lilly Expanded Partnership With Gate Bioscience

The pharmaceutical giant added $870 million in potential payments to its ongoing biotech collaboration.

Updated on Oct. 5, 2026 in Biotech

Isometric editorial illustration featuring a complex protein structure model on a sterile platform, representing biotechnology and medical research. — Eli Lilly has expanded its biotech partnership with Gate Bioscience by committing $870 million in potential payments to advance protein-blocking drug therapies. AI Illustration. Upload story photo >

Live Poll

Do you believe partnerships between big pharmaceutical companies and small biotech firms improve medical innovation?

Eli Lilly has bolstered its alliance with Gate Bioscience by committing an additional $870 million in potential payments. This expansion adds one new drug target to the existing partnership, with an option to select a second target in the future.

Why it matters

The deal strengthens the development pipeline for innovative therapies that use molecular gates to block disease-causing proteins. By targeting the SEC61 channel, the companies aim to address complex conditions such as prion disease.

Gate Bioscience utilizes proprietary molecular gates that recognize unique sequences on diseased proteins to prevent them from exiting the cell. The technology focuses on the SEC61 channel to block harmful proteins at their cellular source.

The players

Eli Lilly

Headquartered in Indianapolis, this global pharmaceutical firm focuses on developing medicines for chronic health conditions.

Gate Bioscience

Based in California, this biotech company specializes in protein-targeted therapies for difficult-to-treat diseases.

The details

Founded in 2021, Gate Bioscience has attracted significant capital, including $60 million in series A financing and $65 million in series B funding. Eli Lilly, which serves as both a partner and an investor, remains deeply embedded in the startup's research efforts.

Gate Bioscience was founded in 2021.
The startup secured $60 million in series A financing in 2023.
Eli Lilly and Gate Bioscience initiated their first partnership in 2025.
Gate Bioscience secured $65 million in series B financing in 2025.

The Tech Race

This deal underscores a broader industry shift toward highly specific, protein-level interventions that replace less precise traditional drug modalities. By betting on SEC61 channel technology, Eli Lilly is positioning itself at the forefront of the next generation of precision biotech.

For patients awaiting new treatments, this expansion represents a significant step toward moving experimental drugs into the development pipeline. While immediate consumer availability is years away, the capital influx ensures that advanced research into prion disease continues to move forward.

The takeaway

Large pharmaceutical companies continue to lean on venture-backed startups to fill their innovation gaps with specialized technology platforms. Investors and observers should monitor how successfully these partnerships translate high-concept protein science into viable clinical candidates.